bluebird bio (BLUE) Tops Q3 EPS by 1c

bluebird bio (NASDAQ: BLUE) reported Q3 EPS of ($0.66), $0.01 better than the analyst estimate of ($0.67). Revenue for the quarter came in at $12.39 million versus the consensus estimate of $13.56 million.

For earnings history and earnings-related data on bluebird bio (BLUE) click here.

You May Also Be Interested In

• Wells Fargo cuts Netflix rating on engagement risk, weak slate
• B.Riley Assumes Anika Therapeutics (ANIK) at Buy
• Element Solutions (ESI) PT Lowered to $47 at UBS, Buy Rating Maintained